141 filings
6-K
NCNA
NuCana plc
1 May 24
Current report (foreign)
4:08pm
6-K
NCNA
NuCana plc
16 Apr 24
NuCana Announces Completion of ADS Ratio Change
8:08am
6-K
NCNA
NuCana plc
9 Apr 24
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy
4:43pm
F-6 POS
NCNA
NuCana plc
27 Mar 24
Automatic registration for ADRs (post-effective amendment, foreign)
5:17pm
424B5
NCNA
NuCana plc
27 Mar 24
Prospectus supplement for primary offering
4:47pm
6-K
zd2se
27 Mar 24
NuCana Announces Plan to Implement ADS Ratio Change
4:39pm
6-K
dtnu85qky
20 Mar 24
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
4:12pm
6-K
7c0mt k3ul4v2
16 Nov 23
Unaudited Condensed Consolidated Statements of Operations
4:08pm
6-K
rokale
13 Nov 23
NuCana Announces Listing Transfer to Nasdaq Capital Market
4:22pm
6-K
hlv pya47
16 Oct 23
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC
7:10am
6-K
y611eey8
13 Oct 23
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
4:09pm
6-K
ql1rjs36r4q9
18 Sep 23
NuCana Announces Presentations at the AACR-NCI-EORTC International
8:10am
6-K
mza81z
16 Aug 23
Unaudited Condensed Consolidated Statements of Operations
4:08pm
6-K
q66bi2jg
16 Jun 23
Current report (foreign)
8:00am
6-K
583m56kqgywmn
17 May 23
Unaudited Condensed Consolidated Statements of Operations
4:07pm
6-K
2tvvin3noyjg2e
15 May 23
Current report (foreign)
4:11pm
6-K
g16bzd q5
12 May 23
NuCana Announces Receipt of Nasdaq Notice
4:15pm
6-K
t5oiog
14 Apr 23
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
8:06am